secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001193125-22-296553
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023
--------------------------------------------------------------------------------

- Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.
- Martin expected to become CEO on July 27, 2023, per settlement with Danaher entities.
- Settlement limits Martin's responsibilities and bars involvement in Nucleic Acid Production segment until July 26, 2023.
- Carl Hull continues as Executive Chairman and interim CEO; lawsuit voluntarily dismissed.
- Christine Dolan remains COO of Biologics Safety Testing segment, reporting to Martin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/0001193125-22-296553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000119312522296553/d428491d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-296553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer